The commercial strategy for ELEVIDYS has pivoted toward a 'balanced discussion' of benefit-risk, with early evidence of success seen in increased enrollment form activity from returning and new treatment sites. The company achieved GAAP and non-GAAP operating profitability, which management views as a critical foundation for independently funding their next-generation siRNA pipeline. Management attributes quarterly performance to the durability of the core PMO franchise and disciplined execution of expanded commercial initiatives for ELEVIDYS. Second-half 2026 revenue is expected to be modestly lower than the first half, as it reflects a period of lower enrollment activity prior to the full deployment of new commercial initiatives. Interim results from the MAD studies for FSHD (SRP-1001) and DM1 (SRP-1003) are expected in the second half of 2026, focusing on establishing the biological chain from tissue exposure to target knockdown.